6M
NBIX icon

6 Meridian’s Neurocrine Biosciences NBIX Stock Holding History

6 Meridian’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$208K Buy
2,448
+17
+0.7% +$1.56K 0.02% 379
2021
Q3 		$233K Buy
+2,431
New +$230K 0.02% 244

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
EVM
Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

6 Meridian's NBIX Position: Q4 2021 in Review

6 Meridian increased its Neurocrine Biosciences (NBIX) stake by 0.7% in Q4 2021, buying an estimated $1.56K and bringing the position to 2,448 shares worth $208K. The position accounts for 0.02% of the portfolio, ranked #379.

6 Meridian first reported a position in NBIX in Q3 2021 and has held it in 2 quarters since. The position peaked at $233K in Q3 2021. 405 funds tracked by Wall St. Rank hold NBIX as of Q4 2021.

  • 6 Meridian held 2,448 shares of Neurocrine Biosciences worth $208K as of Q4 2021.
  • 6 Meridian bought 17 Neurocrine Biosciences shares in Q4 2021, an estimated $1.56K.
  • Neurocrine Biosciences made up 0.02% of 6 Meridian's portfolio in Q4 2021, its #379 holding.
  • 6 Meridian first reported a position in Neurocrine Biosciences in Q3 2021 and has held it in 2 quarters since.
  • 6 Meridian's Neurocrine Biosciences position peaked at $233K in Q3 2021.
  • 405 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2021.

Based on 6 Meridian's 13F filing for Q4 2021, filed 1 Feb 2022.